NEW YORK (360Dx) – Quidel said Wednesday that it has received CE marking for its Thyretain TBI Reporter BioAssay used in the qualitative detection in serum of autoantibodies that block thyroid-stimulating hormone receptors.

Quidel’s assay employs a patented technology to detect thyroid-blocking immunoglobulin (TBI) and enables highly complex laboratories to diagnose autoimmune thyroiditis in a few days. Until now, a method to detect it has not been available in the market, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.